1. Background {#sec157092}
=============

Tuberculosis (TB), a disease as old as human life, remains a serious worldwide health threat ([@A29147R1]). Second-line drugs, which are expensive and toxic, are an inevitable treatment course for *Mycobacterium tuberculosis* isolates that are resistant to first-line medications. This form of *M. tuberculosis* is known as multidrug-resistant *M. tuberculosis* (MDR-*M. tuberculosis*) ([@A29147R2]). Immediate and accurate treatment of TB is essential for controlling the disease; therefore, rapid and accurate detection of drug resistance is a key factor in the effort to control MDR-TB ([@A29147R3]). The proportion method is a standard drug-susceptibility test for detection of drug resistance in *M. tuberculosis* ([@A29147R4]). However, this test demands from eight days to more than one month for completion, a long time for a patient who is likely subjected to suboptimal treatment. Moreover, in most developing countries like Iran, drug-susceptibility tests are available only in reference laboratories, and because of this low availability, results are delayed ([@A29147R5]).

According to broad analyses, mutations in the *rpoB* gene at the 81bp region are the cause of more than 98% of rifampicin (RMP) resistance ([@A29147R6]), and a change in the *katG* 315 codon is the cause of more than 50% of isoniazid (INH) resistance ([@A29147R7]). The world health organization (WHO) recommends the development and implementation of molecular approaches for detecting *M. tuberculosis* drug-susceptibility, especially in developing countries ([@A29147R5]). Real-time polymerase chain reaction (PCR) is a widely used molecular technique, as it is a high-speed method with a low risk of contamination ([@A29147R8]-[@A29147R10]). Melting curve analysis is a simple approach for detecting mutations by real-time PCR ([@A29147R1]).

2. Objectives {#sec157093}
=============

The purpose of this study was to assess the potential of real-time PCR melting curve analysis for the detection of mutations associated with INH and RMP resistance in *M. tuberculosis* clinical isolates.

3. Patients and Methods {#sec157100}
=======================

In a cross-sectional study, 90 patients with pulmonary TB were randomly selected for analysis in 2014 from five border provinces of Iran, including east and west Azerbaijan, Ardebil, Kermanshah and Kurdistan. The university ethics committee code of study was 1391/6/18/5/4/5375.

3.1. Demographic Data and Analysis {#sec157094}
----------------------------------

Demographic and environmental data were collected using a questionnaire. Clinical characteristics were provided using the information mentioned in the surveying of medical records and with the assistance of the physician in charge of the treatment of TB; additional clinical details were obtained from personal interviews and home inspections. The validity and reliability of the questionnaire had been previously confirmed through a pilot study (Cronbach's alpha = 0.98). Data was analyzed using univariate logistic regression in SPSS 18 (233 south Wacker drive, 11th floor, Chicago, Illinois, USA). The validity (sensitivity and specificity) test was done using the OpenEpi online program (open source epidemiologic statistics for public health, version. www.OpenEpi.com).

3.2. Inclusion Criteria {#sec157095}
-----------------------

As determined by ELISA (enzyme-linked immune sorbent assay) test, all patients were HIV negative and received DOTS (directly observed therapy, short-course). The inclusion criteria of the study were smear-positive pulmonary TB with at least two initially positive sputum smears for acid-fast bacilli, or one positive sputum smear and radiographic abnormalities consistent with active pulmonary TB, or one positive smear and positive culture for *M. tuberculosis* ([@A29147R11]). The *M. tuberculosis* complex was identified by culturing on Lowenstein-Jensen (LJ) medium containing p-nitro benzoic acid. The *M. tuberculosis* species was identified based on a niacin test and a nitratase test (a positive reaction of a pink color indicated nitrate had been reduced to nitrite ([@A29147R12]).

3.3. Standard Proportion Test {#sec157096}
-----------------------------

A drug-susceptibility test was carried out in LJ medium according to the proportion method recommended by WHO/IUTLD ([@A29147R11]) using INH: 0.2 mg/L, RMP: 40 mg/L. Incubation of the samples was continued for 43 days.

3.4. DNA Extraction {#sec157097}
-------------------

DNA was extracted from clinical isolates grown on LJ medium in the following process: at least two to three *M. tuberculosis* colony loops were suspended in 1X TE buffer, inactivated at 80°C for 20 minutes, washed three times with 1X TE, and incubated with lysozyme at 37°C for 24 hours. Afterward, proteinase K was added, and the samples were incubated at 65°C for another 24 hours. After adding CTAB/NaCl + 5M NaCl and chloroform/isoamyl alcohol, isopropanol was added to each sample and maintained in a -20°C freezer for 24 hours. Finally, after washing the DNA with 70% ethanol, the DNA was dissolved in 30 μL of distilled water and preserved at -20°C until use ([@A29147R13]).

3.5. Real-Time PCR {#sec157098}
------------------

Three dually labeled probes and four primers were designed to detect two genes associated with drug resistance. Usually, more than four probes should be used to assess the 81 bp region of the *rpoB* gene ([@A29147R1], [@A29147R2], [@A29147R14]). We designed two long probes to detect mutations at *rpoB* for decreasing workload and consuming costs. The sequence of primers (forward and in reverse) and probes in *rpoB* 511 to 519 and 524 to 533 codons, and 315 codons *katG* genes are described in [Table 1](#tbl40057){ref-type="table"} ([@A29147R1]).

###### The Sequence of Primers and Probes in *rpoB* and *katG* Codons ([@A29147R1])

  Detection Target         Probes (5\'-3\')                         Forward Primers (5\'-3\')       Reverse Primers (5\'-3\')
  ------------------------ ---------------------------------------- ------------------------------- -------------------------------
  ***katG315***            TCA CCA GCG GCA TCG                      CGT ATG GCA CCG GAA CCG GTA A   GCT CCC ACT CGT AGC CCG TAC A
  ***rpoB*** **511-519**   GGT TGT GGT CCA GAA TTG GCT CAG C        GCC GCG ATC AAG GAG TTC TTC     CGG CAC GCT CAC GTG ACA GAC
  ***rpoB*** **524-533**   GCC CCA GCG TCG ACA GCG GTG CTT GTC GG                                   

The content of real-time PCR reaction in a thermal cycler (applied biosystems® thermal cyclers CA, USA) with a total volume of 20 μL was as follows: PCR master mix (premix Ex Taq, Takara Bio Inc., Japan): 10 μL, primer mix (Forward-Reverse): 0.25 μL, probe: 0.5 μL, Rox reference Dye (Takara Bio Inc., Japan): 1 μL, sterilized distilled water: 7.25 μL and extracted DNA with the maximum concentration of 100 ng: 1 μL. PCR conditions were as follows: primary denaturation at 95°C for 10 minutes followed by denaturation at 95°C, 10; annealing at 58°C for 30 seconds and extending 72°C for 15 seconds (40 cycle). Each probe had a different melting condition in PCR so that, for rpoΒ 511 to 519: 95°C at 15 seconds; 58°C at 15 seconds; 95°C at 15. For *rpoΒ* 524 to 533: 95°C at 15; 58°C at 15; 95°C at 15 and melt *katG* 315: 95°C at 15 seconds; 55°C at 15 seconds; 95°C at 15 seconds. The isolates with a melting temperature (Tm) difference of 1.5°C (compared to the Tm of sensitive isolates) were considered as mutant isolates ([@A29147R1], [@A29147R2], [@A29147R14]).

3.6. Multiplex Allele-Specific PCR (MAS-PCR) {#sec157099}
--------------------------------------------

Using the MAS-PCR technique, codon 315 of the *katG* gene and codons 516, 526 and 531 of the *rpoB* gene were evaluated. Four allele-specific primers corresponding to the four target codons and two common primers were used in the MAS-PCR assay as described by Yang et al. ([@A29147R15]). The MAS-PCR reaction was prepared in a 25 μL volume and contained 1 μL primer mix (6 primers: *rpoB* 516, *rpoB* 526, *rpoB* 531, *RRm*, *katG* FC, *katG* RC), 10 μL master mix (Ampliqon, Denmark), 1 μL DNA (with a concentration of at least 100 ng/µL) and 13 μL of distilled water. The thermal cycler (PeQ lab, primus 96, Germany) conditions followed were: initial denaturizing at 94°C for 7 minutes, 35 cycles of 94°C for 30 seconds, 68°C for 40 seconds and a final extension at 72°C for 5 minutes ([Figure 1](#fig29413){ref-type="fig"}).

![Melting Temperature Curve Analysis for 46 MTB Patients by *katG315*](jjm-09-10-29147-i001){#fig29413}

4. Results {#sec157105}
==========

4.1. Descriptive Results {#sec157101}
------------------------

The studied isolates were collected from 90 patients with an average age of 54.35 years (ranging from 15 - 83); 44 cases (48.9%) were male and 46 cases (51.1%) female. The content of sampling in different provinces was as follows: 28 cases (31.1%) were from east Azerbaijan, 25 cases (27.8%) from West Azerbaijan, 9 cases (10%) from Ardebil, 16 cases (17.8%) from Kermanshah and 12 cases (13.3%) from Kurdistan. TB category II or patients who are either diagnosed with a previous infection of TB or who have received the first line drugs but have faced failure, relapse or drug resistance during the treatment, had a shortage of access to drugs, or have encountered faults in receiving the treatment plan from health care providers, was detected in 9 (10%) patients. Seventy-seven percent of patients in category II had mutations in their *katG* and *rpoB* genes.

4.2. Real-Time PCR Results {#sec157102}
--------------------------

Melting curve method was used to study mutations associated with drug resistance. The mutations were detected by comparing the Tm of amplicons of resistant isolates with that of susceptible isolates. The frequency of all mutations was 23, where the frequency of mutations was nine for *rpoB* P1, 7 for *rpoB* P2 and 7 for *katG* 315. The frequency of isolates with at least one mutation in *rpoB* or *katG* was 11 cases. The frequency of mutations at *katG* 315 and *rpoB* P1 or *rpoB* P2 (in the likelihood of MDR-TB) was three cases ([Figure 2](#fig29414){ref-type="fig"}). The average Tm and standard deviation (SD) of susceptible isolates was as follows: 315 *katG* codon 85.4, 0.18; *rpoΒ* P1 sequence 84.6, 0.6 and *rpoΒ* P2 sequence 83.4, 0.18 ([Table 2](#tbl40058){ref-type="table"})

![Melting Temperature Curve Analysis for 46 *M. tuberculosis* Patients by *rpoB* P1](jjm-09-10-29147-i002){#fig29414}

###### Melt Temperature Results in *katG* 315, *rpoB* P1 and *rpoB* P2 Sequences

  Type Mutation   TM, °C (SD) Susceptible Isolates   TM, °C (SD) Mutant Isolates   Mean Difference, °C
  --------------- ---------------------------------- ----------------------------- ---------------------
  **katG 315**    85.4 (0.18)                        87.54 (0.62)                  2.14
  **rpoB P1**     84.6 (0.61)                        82.9 (0.38)                   -1.7
  **rpoB P2**     83.37 (0.18)                       85.27 (0.19)                  1.9

The average Tm of *rpoB* P1 in mutant isolates was 82.9 (SD: 0.38). In other words, mutant isolates in *rpoB* 511 to 519 codons were accompanied by a Tm decrease of 1.7°C ([Table 2](#tbl40058){ref-type="table"}). The Tm of *rpoB* P2 in mutant isolates was 85.3 (SD: 0.19). This implies that mutations in *rpoB* 524 to 533 codons were accompanied by a Tm increase (1.9 °C). Therefore, a difference of more than two standard deviations from the *rpoB* P1 Tm and a difference of 10 standard deviations from the *rpoB* P2 Tm significantly accompanies mutation isolates. The average Tm in *katG* 315 in mutant isolates was 87.54°C (SD: 0.62) which was increased by 2.1°C compared with 315 *katG* Tm in susceptible isolates ([Table 2](#tbl40058){ref-type="table"}). It should be noted that three isolates displayed a 3.42°C decrease in the *katG* Tm, and were removed from analysis ([Figure 2](#fig29414){ref-type="fig"}). The distribution of frequency of *katG* and *rpoB* mutations based on provinces is shown in [Table 3](#tbl40059){ref-type="table"}.

###### Frequency of Mutations in *katG* and *rpoB* Codons Based on Various Provinces^[a](#fn43348){ref-type="table-fn"},[b](#fn43349){ref-type="table-fn"}^

  Provinces (Number)          Frequency of *katG* Mutation   Frequency of *rpoB* Mutation   Frequency of Both *katG* and *rpoB* Mutation
  --------------------------- ------------------------------ ------------------------------ ----------------------------------------------
  **East Azerbaijan (28)b**   1 (4.0)                        4 (14.3)                       1 (4.0)
  **West Azerbaijan (25)**    1 (4.0)                        4 (16.0)                       0 (0.0)
  **Ardabil (9)**             3 (33.3)                       1 (11.1)                       1 (11.1)
  **Kermanshah (16)**         1 (6.25)                       4 (25.0)                       0 (0)
  **Kurdistan (12)**          3 (25.0)                       1 (8.3)                        1 (8.3)
  **Total (90)**              9 (8.0)                        14 (15.6)                      3 (3.3)

^a^Value are expressed as No. (%).

^b^3 of 28 isolates were removed from *katG* mutation analysis.

4.3. Comparison of Real-Time PCR Results and Standard Proportion Test {#sec157103}
---------------------------------------------------------------------

In this study, eight and 12 cases had resistance to INH and RMP, respectively. However, 4.4% (four cases) were MDR, i.e., they showed resistance to both INH and RMP. The sensitivity and specificity of real-time PCR in the detection of INH resistance were 75% (CI 95%; 40.93, 92.85) and 97.47%, respectively (CI 95%; 91.23, 99.3); in the detection of RMP resistance, its sensitivity and specificity were 83.3% (CI 95%; 55.2, 95.3) and 98.72% (CI 95%; 93.09, 99.77) ([Table 4](#tbl40060){ref-type="table"}).

###### Diagnostic of INH and RMP Resistance Test Evaluation of MTB Tuberculosis Patients in Real-Time PCR Results

  Real Time-PCR Test                              Proportion Test     Sensitivity (CI 95%)   Specificity (CI 95%)   
  ----------------------------------------------- ------------------- ---------------------- ---------------------- -----------------------
  ***katG***                                      Resistance to INH   Sensitive to INH       75% (40.93, 92.85)     97.47% (91.23, 99.3)
  *katG 315* mutation                             6                   2                                             
  Without mutation in *katG 315*                  2                   77                                            
  ***rpoB***                                      Resistance to RMP   Sensitive to RMP       83.3% (55.29, 95.3)    98.72% (93.72, 99.77)
  *rpoB* codons(P1 and P2) mutation               10                  1                                             
  Without mutation in *rpoB* codons (P1 and P2)   2                   77                                            

4.4. Comparison of Real-Time PCR Results With MAS-PCR {#sec157104}
-----------------------------------------------------

The sensitivity and specificity of real-time PCR technique in identifying *katG* mutation by MAS- PCR were 100.0% (CI 95%; 51.0, 100.0) and 95.18% (CI 95%; 88.25, 98.11), respectively; in detection of mutation in *rpoB* codons (516, 526 and 531) its sensitivity and specificity were 80.0% (CI 95%; 49.02, 94.33) and 96.25% (CI 95%; 89.55, 98.72), respectively ([Table 5](#tbl40061){ref-type="table"}).

###### Diagnostic of *katG* 315 and *rpoB* (codons 516, 526 and 531) Mutation Test Based MAS-PCR Evaluation of MTB Tuberculosis Patients in Real-Time PCR Results

  Real Time-PCR Test                              MAS-PCR Test                                  Sensitivity (CI 95%)                                  Specificity (CI 95%)   
  ----------------------------------------------- --------------------------------------------- ----------------------------------------------------- ---------------------- -----------------------
  ***katG***                                      *KatG 315* mutation                           Without mutation in *KatG 315*                        100% (51.01, 100)      95.18% (88.25, 98.11)
  *katG 315* mutation                             4                                             4                                                                            
  Without mutation in *katG 315*                  0                                             79                                                                           
  ***rpoB***                                      mutation in *rpoB* (516,526 and 531) codons   Without mutation in *rpoB* (516,526 and 531) codons   80.0% (49.02, 94.33)   96.25% (89.55, 98.72)
  *rpoB* codons (P1 and P2) mutation              8                                             3                                                                            
  Without mutation in *rpoB* codons (P1 and P2)   2                                             77                                                                           

Studies of the relationship between age and mutation odds in the *rpoB* gene revealed a significant statistical relationship (β = 0.85 and P = 0.046). It was observed, however, that a previous history of using TB drugs increased mutation odds at rpoB (OR = 16 and P = 0.036) while gender, household size number, immigration history and smoking did not (P \> 0.005). There was also no significant relationship between the above-mentioned variables and mutation odds in *katG 315* (P \> 0.005).

5. Discussion {#sec157106}
=============

The global incidence of TB drug resistance is very high in TB patients with a recurring illness. The recurrence rate in low- and middle-income countries is estimated to be approximately 10 - 20% ([@A29147R16]). In 2004, approximately 6.8% of the TB patients in Iran were in the recurrent group ([@A29147R17]). We found that 7.2% of the patients in our previous study had recurrent TB ([@A29147R17]). In the present study, 10% of patients were diagnosed with recurrent TB. The higher frequency of mutations (25%) in the present study might be due to a higher proportion of recurrent TB in isolates in this study (10%).

Mohajeri et al. (2015) used a density array (LCD-array) to detect mutations within the 90-bp *rpoB* region in the sputum of TB patients from western Iran. Of the 125 *M. tuberculosis* isolates, 35 subjects (28%) were found to be rifampicin resistant ([@A29147R18]). This result had c very close to consistent with our study (25%).

In this study, we performed an inexpensive and rapid test using a real-time PCR approach, employing melting curve analysis of dually labeled probes in order to detect current mutations leading to INH and RMP resistance. A number of similar studies have used melting curve analysis based on FRET (fluorescence resonance energy transfer) probes to detect current mutations in TB ([@A29147R1], [@A29147R10], [@A29147R14], [@A29147R15]). In our current study, the maximum mean SD of Tm in susceptible isolates was 0.61°C. On the other hand, the minimum distance between Tm in susceptible isolates and mutant isolates was above 1.7°C (related to *rpoB*). This implies that the detection of mutations using the melting analysis technique provided a higher differentiating ability. In some previous studies ([@A29147R8], [@A29147R14], [@A29147R19]), Tm of *katG* and *rpoB* in mutant isolates differed more than two standard deviations from the average Tm of susceptible species. Torres et al. ([@A29147R19]) studied 30 RMP-resistant isolates using two pairs of primers. They showed a decrease by 6°C in Tm of mutant isolates in *rpoB* 513 to 516 codons, but an increase by 2°C in Tm of mutant isolates in *rpoB* 526 to 531 codons ([@A29147R19]). In Garcia de Viedma et al. study ([@A29147R20]), the isolates with mutation in *rpoB* 515 and 516 codons showed a decrease of 2.48 - 8.39°C in Tm, while codons 526 and 531 showed a decrease of 6.92°C, which is inconsistent with our results.

Torres et al. showed that the average Tm of *katG* 315 in susceptible species was 72.8°C ([@A29147R19]). Also, Marin et al. estimated an average of 70.85°C of Tm in the 315 *katG* codon in susceptible species ([@A29147R14]). According to our study\'s estimations, the average Tm of *katG* of mutated species was 87.54°C. In our current study, 83.3% of RMP-resistant isolates were detected by real-time PCR technique using two probes that included codons 513 to 516 and codons 526 to 531. However, 75% of INH-resistant isolates were detected by this technique. It should be noted that the result of the real-time PCR test was blind to the proportional test result.

In this study, 80.0% of *rpoB* codon mutations in MAS-PCR were detected by real-time PCR technique using two probes including codons 513 to 516 and codons 526 to 531. However, 100% of *katG* mutations were detected by this technique. In the study by Feizabadi et al. (2009 - 2012) on *M. tuberculosis* clinical isolates, the sensitivity and specificity of RMP resistance detection by high-resolution melting curve (HRM) analysis of the 129-bp fragment of *rpoB* were estimated at 95% and 100%, respectively. Also, sensitivity and specificity of INH resistance detection by HRM analysis were reported at 85.7% and 100%, respectively ([@A29147R21]).

Sheikholslami et al. (2011) calculated the validity of single-strand confirmation polymorphism to detect drug resistance compared to DNA sequencing. The sensitivity and specificity of this assay in detection of the *rpoB* gene were 70.8% and 88%, respectively ([@A29147R22]). It is clear from our research that, previous history of TB treatment and aging increased the odds of RMP resistance. A great number of studies, however, have found a significant relationship between previous history of TB treatment and drug resistance ([@A29147R20], [@A29147R23], [@A29147R24]), while there are contradictory findings regarding the relationship between age and mutation odds ([@A29147R20], [@A29147R23]). The limitation of this study was its low budget, so it was not possible to perform the study on a higher sample size. Also, the role of mutation of *inhA*, *ahp* and *oxyR* genes in the creation of INH resistance was not identified.

In conclusion, the detection of drug-resistant mutations through melting analysis technique had a high differentiating ability. It is essential to monitor older patients and those with a previous history of TB treatment using rapid and accurate techniques t of determining their drug resistance odds.

The authors thank the following persons and institutions: the staff of the east Azerbaijan reference laboratory, TB and lung disease research center and province health center. At Tabriz University of Medical Sciences: Maryam Seyyedi, BSC of lab sciences; Dr. Seyyed Reza Moaddab, Ph.D. microbiologist; Jalil Rashedi, MS.c of microbiology; Ahad Zarei, BSC of lab sciences; Hasan Yekrang, Ms.c of health service management; Dr. Simin Khayyat Zadeh, MD. At workers of west Azerbaijan laboratory and province health center: Dr. Tavana, MD; Dr. Nemati, MD; Mr. Seyyedi and Sarhangi, BSC of lab sciences. Workers of Ardabil laboratory and province health center: Dr. Arezu Moini, MD, and Mrs. Saraii, BSC of lab sciences. Workers of the Kermanshah reference laboratory: Sara Atashi, BSC of lab sciences; Parviz Mohajeri, microbiologist; Kamalledin Jadidian, M.Sc. of microbiology. Workers of Kurdistan laboratory and province health center: Mr. Galilini, BSC of lab sciences, and Lesley Carson, for editorial assistance.

**Authors' Contribution:**Leyla Sahebi and Khalil Ansarin researched and wrote the study design; Leyla Sahebi collected data; Seiran Nili and Majid Khalili helped collect the data; Leyla Sahebi and Amir Monfaredan performed the study design; Leyla Sahebi, Amir Monfaredan and Khalil Ansarin interpreted the data; Leyla Sahebi and Safar Farajnia wrote the manuscript all authors read and approved the final manuscript.
